Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.

Linette GP, Becker-Hapak M, Skidmore ZL, Baroja ML, Xu C, Hundal J, Spencer DH, Fu W, Cummins C, Robnett M, Kaabinejadian S, Hildebrand WH, Magrini V, Demeter R, Krupnick AS, Griffith OL, Griffith M, Mardis ER, Carreno BM.

Proc Natl Acad Sci U S A. 2019 Nov 19;116(47):23662-23670. doi: 10.1073/pnas.1906026116. Epub 2019 Nov 4.

PMID:
31685621
2.

Regulation of toxic shock syndrome toxin-1 by the accessory gene regulator in Staphylococcus aureus is mediated by the repressor of toxins.

Tuffs SW, Herfst CA, Baroja ML, Podskalniy VA, DeJong EN, Coleman CEM, McCormick JK.

Mol Microbiol. 2019 Oct;112(4):1163-1177. doi: 10.1111/mmi.14353. Epub 2019 Jul 30.

PMID:
31321813
3.

The SaeRS Two-Component System Is a Direct and Dominant Transcriptional Activator of Toxic Shock Syndrome Toxin 1 in Staphylococcus aureus.

Baroja ML, Herfst CA, Kasper KJ, Xu SX, Gillett DA, Li J, Reid G, McCormick JK.

J Bacteriol. 2016 Sep 9;198(19):2732-42. doi: 10.1128/JB.00425-16. Print 2016 Oct 1.

4.

Superantigens subvert the neutrophil response to promote abscess formation and enhance Staphylococcus aureus survival in vivo.

Xu SX, Gilmore KJ, Szabo PA, Zeppa JJ, Baroja ML, Haeryfar SM, McCormick JK.

Infect Immun. 2014 Sep;82(9):3588-98. doi: 10.1128/IAI.02110-14. Epub 2014 Jun 9.

5.

Bacterial superantigens promote acute nasopharyngeal infection by Streptococcus pyogenes in a human MHC Class II-dependent manner.

Kasper KJ, Zeppa JJ, Wakabayashi AT, Xu SX, Mazzuca DM, Welch I, Baroja ML, Kotb M, Cairns E, Cleary PP, Haeryfar SM, McCormick JK.

PLoS Pathog. 2014 May 29;10(5):e1004155. doi: 10.1371/journal.ppat.1004155. eCollection 2014 May.

6.

Immunosuppression involving soluble CD83 induces tolerogenic dendritic cells that prevent cardiac allograft rejection.

Ge W, Arp J, Lian D, Liu W, Baroja ML, Jiang J, Ramcharran S, Eldeen FZ, Zinser E, Steinkasserer A, Chou P, Brand S, Nicolette C, Garcia B, Wang H.

Transplantation. 2010 Dec 15;90(11):1145-56. doi: 10.1097/TP.0b013e3181f95718.

PMID:
20861805
7.

Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance.

Ge W, Jiang J, Baroja ML, Arp J, Zassoko R, Liu W, Bartholomew A, Garcia B, Wang H.

Am J Transplant. 2009 Aug;9(8):1760-72. doi: 10.1111/j.1600-6143.2009.02721.x. Epub 2009 Jun 26.

8.

Abnormal immunological profile and vaginal microbiota in women prone to urinary tract infections.

Kirjavainen PV, Pautler S, Baroja ML, Anukam K, Crowley K, Carter K, Reid G.

Clin Vaccine Immunol. 2009 Jan;16(1):29-36. doi: 10.1128/CVI.00323-08. Epub 2008 Nov 19.

9.

Receptor-interacting protein 2 is a marker for resolution of peritoneal dialysis-associated peritonitis.

McCully ML, Baroja ML, Chau TA, Jain AK, Barra L, Salgado A, Blake PG, Madrenas J.

Kidney Int. 2007 Nov;72(10):1273-81. Epub 2007 Sep 12.

10.

Bacterial superantigens bypass Lck-dependent T cell receptor signaling by activating a Galpha11-dependent, PLC-beta-mediated pathway.

Bueno C, Lemke CD, Criado G, Baroja ML, Ferguson SS, Rahman AK, Tsoukas CD, McCormick JK, Madrenas J.

Immunity. 2006 Jul;25(1):67-78.

11.

Human embryonic stem cells possess immune-privileged properties.

Li L, Baroja ML, Majumdar A, Chadwick K, Rouleau A, Gallacher L, Ferber I, Lebkowski J, Martin T, Madrenas J, Bhatia M.

Stem Cells. 2004;22(4):448-56.

12.

Regulation of T-cell activation by phosphodiesterase 4B2 requires its dynamic redistribution during immunological synapse formation.

Arp J, Kirchhof MG, Baroja ML, Nazarian SH, Chau TA, Strathdee CA, Ball EH, Madrenas J.

Mol Cell Biol. 2003 Nov;23(22):8042-57.

13.

Viewpoint: therapeutic implications of CTLA-4 compartmentalization.

Baroja ML, Madrenas J.

Am J Transplant. 2003 Aug;3(8):919-26. Review.

14.
15.

Inhibition of CTLA-4 function by the regulatory subunit of serine/threonine phosphatase 2A.

Baroja ML, Vijayakrishnan L, Bettelli E, Darlington PJ, Chau TA, Ling V, Collins M, Carreno BM, Madrenas J, Kuchroo VK.

J Immunol. 2002 May 15;168(10):5070-8.

16.

CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression.

Carreno BM, Bennett F, Chau TA, Ling V, Luxenberg D, Jussif J, Baroja ML, Madrenas J.

J Immunol. 2000 Aug 1;165(3):1352-6.

17.

The inhibitory function of CTLA-4 does not require its tyrosine phosphorylation.

Baroja ML, Luxenberg D, Chau T, Ling V, Strathdee CA, Carreno BM, Madrenas J.

J Immunol. 2000 Jan 1;164(1):49-55.

18.

Specific CD3 epsilon association of a phosphodiesterase 4B isoform determines its selective tyrosine phosphorylation after CD3 ligation.

Baroja ML, Cieslinski LB, Torphy TJ, Wange RL, Madrenas J.

J Immunol. 1999 Feb 15;162(4):2016-23.

19.

The complete genomic sequence of an HTLV-II isolate from a Guahibo Indian from Venezuela.

Dube S, Love JL, Dube DK, Leon-Ponte M, de Perez GE, Baroja ML, Bianco N, Poiesz BJ.

Virology. 1999 Jan 20;253(2):181-92.

20.

T cell hyperreactivity to IL-6 in chronic nonviremic HBV carriers despite normal IL-6 receptor or gp130 expression.

Baroja ML, Sirit FL, Rivera H, Garzaro J, Bianco NE, Machado IV.

Viral Immunol. 1996;9(3):187-94.

PMID:
8890477
21.

[Immunoclinical, molecular and immunopathologic approach to chronic viral hepatitis. Therapeutic considerations].

Machado IV, Deibis L, Risquez E, Tassinari P, Zabaleta ME, Toro FI, Baroja ML, Corado J, Ruiz ME, Longart L, et al.

G E N. 1994 Jul-Sep;48(3):124-32. Spanish.

PMID:
7768416
22.

CD3- and CD28-activating pathways in HCV infection.

Corado JA, Toro FI, Baroja ML, Bianco NE, Machado IV.

Viral Immunol. 1994;7(1):37-40.

PMID:
7986335
23.

Anti-CD3-activated T cells from chronic nonviremic HBV carriers are hyperreactive to monocytic accessory signals.

Baroja ML, Sirit FL, Caldera DJ, Toro FI, Zabaleta ME, Colmenares CJ, Bianco NE, Machado IV.

Clin Immunol Immunopathol. 1993 Nov;69(2):180-8.

PMID:
8403555
24.

Enhanced CD3-mediated T lymphocyte proliferation in patients with systemic lupus erythematosus.

Stekman IL, Blasini AM, Leon-Ponte M, Baroja ML, Abadi I, Rodriguez MA.

Arthritis Rheum. 1991 Apr;34(4):459-67.

PMID:
1826426
25.
26.

IL-6 is an accessory signal in the alternative CD2-mediated pathway of T cell activation.

Lorré K, Van Damme J, Verwilghen J, Baroja ML, Ceuppens JL.

J Immunol. 1990 Jun 15;144(12):4681-7.

PMID:
1972166
27.

Accessory cell-derived helper signals in human T-cell activation with phytohemagglutinin: induction of interleukin 2-responsiveness by interleukin 6, and production of interleukin 2 by interleukin 1 [corrected].

Kuhweide R, Van Damme J, Lorre K, Baroja ML, Tsudo M, Ceuppens JL.

Cytokine. 1990 Jan;2(1):45-54. Erratum in: Cytokine 1990 May;2(3):229.

PMID:
2104213
29.

Human T cell activation with phytohemagglutinin. The function of IL-6 as an accessory signal.

Ceuppens JL, Baroja ML, Lorre K, Van Damme J, Billiau A.

J Immunol. 1988 Dec 1;141(11):3868-74.

PMID:
3263438
30.
31.
32.
33.

Helper activity by human large granular lymphocytes in in vitro immunoglobulin synthesis.

Rodriguez MA, Blanca I, Baroja ML, Arama S, Leon-Ponte M, Abadi I, Bianco NE.

J Clin Immunol. 1987 Sep;7(5):356-64.

PMID:
2958493
34.
35.

Abnormal immunoglobulin and rheumatoid factor synthesis by blood lymphocytes in patients with primary Sjögren's syndrome.

Rodriguez MA, Baroja ML, Leon-Ponte M, Abadi I.

Arthritis Rheum. 1986 Dec;29(12):1446-55.

PMID:
2948511
37.

Effect of T3 modulation on pokeweed mitogen-induced T cell activation: evidence for an alternative pathway of T cell activation.

Ceuppens JL, Meurs L, Baroja ML, Van Wauwe JP.

J Immunol. 1986 May 1;136(9):3346-50.

PMID:
3007616

Supplemental Content

Loading ...
Support Center